Biological Embedding of Adverse Childhood Experiences: Neurobiological and Immune Mechanisms Linking Early-Life Stress to Addiction Vulnerability

SAMANTHA E. CLARK, MA; MOLLIE MONNIG, PhD; PETER MONTI, PhD

ABSTRACT

Adverse childhood experiences (ACEs) are associated with elevated risk for substance use disorders (SUDs), yet prevailing accounts often emphasize psychosocial pathways and reward-circuit recalibration without fully articulating immunobiological mechanisms that may converge on these processes. This narrative review advances a biological embedding framework linking early adversity to SUD vulnerability through two partially overlapping pathways: 1) stress–reward neurodevelopmental recalibration and 2) immune embedding with downstream neuroimmune feedback. Drawing on epidemiologic and mechanistic studies across developmental psychopathology, addiction neuroscience, and psychoneuroimmunology, we synthesize evidence that ACE exposure can produce enduring alterations in stress-regulatory systems (e.g., hypothalamic-pituitary-adrenal axis and autonomic function) alongside low-grade inflammatory phenotypes characterized by altered cytokine signaling and glucocorticoid sensitivity. We then highlight convergent evidence that peripheral immune activation can influence central reward and affective processes via microglial priming, cytokine-mediated modulation of monoaminergic systems (particularly dopamine), and tryptophan-kynurenine metabolism, potentially contributing to anhedonia, negative affect, and craving-relevant reinforcement dynamics. Next, we describe limitations of the present review and of the broader evidence base, as well as priority research directions. We conclude by arguing that integrating immune embedding with stress-reward recalibration may clarify one pathway by which ACEs confer SUD vulnerability and may inform trauma-informed, neurobiologically grounded approaches to prevention and treatment.

KEYWORDS: Adverse childhood experiences; substance use disorder; alcohol use disorder; biological embedding; inflammation

INTRODUCTION

Substance use disorders (SUDs) emerge from complex, multilevel processes that begin long before substance use initiation. Among the early-life conditions that shape these trajectories, adverse childhood experiences (ACEs) stand out as particularly consequential. ACEs comprise 10 forms of household-level adversity—including abuse, neglect, and chronic family dysfunction—that capture recurrent disruptions in caregiving environments during formative periods of development.[1,2] Across epidemiologic studies, higher ACE burden is associated with earlier initiation,[3] more rapid escalation,[4] and more persistent, hazardous substance-use trajectories.[4-6] These associations extend to SUD onset[7] and severity[3,4,8] and typically show dose–response gradients.[3,4,8] Clinical data parallel these trends. Individuals entering SUD treatment commonly report substantial early adversity,[9] and higher ACE scores often coincide with more severe disorder presentations,10 greater psychiatric comorbidity,[11] and more limited improvement during treatment.[12,13] Such findings indicate that ACEs are not merely correlates of substance misuse but formative conditions that alter developmental risk architecture, shaping how individuals engage with stress and reward across the lifespan.

The developmental impact of ACEs is increasingly understood through the framework of biological embedding, whereby early adversity calibrates the developing brain and body in enduring ways, shaping the maturation and long-term functioning of key regulatory systems.[14] In particular, two partially overlapping pathways appear especially influential in shaping vulnerability to substance use: 1) a stress–reward neurodevelopmental pathway, in which chronic activation of stress physiology alters the maturation and connectivity of limbic–prefrontal circuits; and 2) an immune-embedding pathway, in which sustained inflammatory activity feeds back on the brain through neuroimmune signaling. Together, these alterations may operate both independently and in concert, establishing a biological milieu in which substance exposure more readily promotes maladaptive, self-reinforcing use patterns. The sections that follow review epidemiologic evidence linking ACEs to substance-use trajectories and then synthesize mechanistic findings that clarify how early adversity becomes biologically embedded through these two pathways. We conclude with a description of limitations and future research directions.

EPIDEMIOLOGICAL FINDINGS ON ACES AND SUBSTANCE USE

ACEs are notable for the consistency and magnitude of their association with substance-related outcomes. Across large cohort and survey studies, higher ACE scores are linked to characteristic alterations in substance-use trajectories, including earlier initiation,[3] more rapid transition from experimentation to regular use,[4] and greater persistence of high-risk patterns into adulthood.[4,5] These developmental shifts correspond with substantial increases in risk. Individual ACE categories are associated with roughly two- to four-fold higher odds of early initiation of illicit drug use, and risk increases in graded fashion with higher cumulative scores.[15] At the highest levels of adversity, this gradient steepens further, with individuals reporting four or more ACEs exhibiting approximately four- to twelve-fold higher odds of problematic alcohol or drug use compared with those reporting none.[16,17] Importantly, these associations broadly generalize across alcohol, opioids, stimulants, and polysubstance involvement,[8] suggesting that early adversity confers a broad liability toward dysregulated reinforcement rather than a narrow, drug-specific vulnerability.

NEUROBIOLOGICAL EMBEDDING OF ACES (PATHWAY 1)

Stress System Adaptations

One way early adversity may shape SUD risk is by recalibrating the developing stress-response system, particularly the hypothalamic-pituitary-adrenal (HPA) axis. In typical development, cortisol secretion follows a diurnal rhythm and is tightly regulated by glucocorticoid receptor (GR)-mediated negative feedback.[18] Chronic childhood adversity, however, can disrupt this calibration. Excessive or recurrent HPA activation during sensitive developmental periods can induce adaptive but ultimately dysregulating changes in HPA set points and responsivity.[19-22] Studies of children and adults with high ACE exposure frequently document altered diurnal cortisol patterns, including flattened slopes and elevated afternoon or evening cortisol, as well as atypical cortisol reactivity profiles, with either blunted or exaggerated responses to acute stress depending on the timing, chronicity, and severity of adversity exposure.[19-24] These findings align with widely cited stress-response models positing an initial phase of hyperreactivity followed by counter-regulatory hyporeactivity under sustained demand.[20]

A common thread across these endocrine phenotypes is diminished GR sensitivity. Evidence from peripheral and central studies suggests that chronic early stress weakens the body's ability to regulate the HPA axis through cortisol, its primary glucocorticoid hormone. Peripherally, adolescents with adversity histories show elevated cumulative cortisol output alongside reduced suppression of T-cell activation by dexamethasone, consistent with partial glucocorticoid resistance.[25] At the neural level, ACEs such as childhood maltreatment have been linked to increased methylation of the exon 1F NR3C1 promoter and reduced GR mRNA expression in hippocampal tissue.[26] Moreover, because GRs are densely expressed in the amygdala, hippocampus, and prefrontal cortex, weakened feedback can prolong or dysregulate cortisol signaling in these regions, increasing susceptibility to structural and functional alterations.[24,27]

Neuroimaging findings provide support for this mechanistic account. In some functional imaging studies, ACE exposure is associated with heightened amygdala reactivity to emotional or threatening cues and reduced recruitment of medial and lateral PFC regions during cognitive control or reappraisal tasks in both adolescents and adults.[28,29] Structural imaging work similarly reports reduced hippocampal and, in some samples, smaller medial PFC and amygdala volume among those with documented childhood trauma.[28,30] Diffusion tensor imaging extends evidence from regional effects to circuit integrity, documenting weaker white-matter connectivity in frontal-limbic pathways, including tracts linking the amygdala and PFC.[29] Collectively, these results suggest a developmental calibration toward a stress-sensitized phenotype, wherein rapid bottom-up threat detection is more readily engaged and prefrontal modulation and hippocampal contextualization are less effective.[28,29] This phenotype is clinically meaningful because heightened negative affect in the setting of diminished regulatory capacity can make the rapid affective relief produced by substances especially reinforcing, amplifying risk for escalation and compulsive patterns of use.[31]

Reward System Adaptations

ACEs may also shape the development of the brain's reward circuitry.[8,32] The mesocorticolimbic dopamine system—encompassing dopaminergic neurons in the ventral tegmental area (VTA) and projections to the PFC, nucleus accumbens (NAc), amygdala, and hippocampus—underlies motivation, pleasure, and reinforcement learning.[32] This system undergoes protracted maturation from childhood through adolescence, making it particularly sensitive to environmental input.[32] Converging evidence suggests that early adversity can recalibrate this circuit, often in the direction of reduced responsiveness to natural rewards.[8,32] At the behavioral level, children and adolescents exposed to maltreatment or neglect frequently show dampened responsiveness to positive outcomes and altered reward-based learning.[8,32] On tasks that require rapid responding to obtain incentives, maltreated youth may respond more slowly, earn fewer rewards, or fail to adjust behavior when contingencies change.[8,32] They also often display increased impulsivity and risk-taking, which may reflect attempts to compensate for a muted sense of reward or difficulty integrating feedback about long-term consequences.[8,32] Mechanistically, these behavioral patterns are consistent with a reward system that is less responsive to everyday reinforcers and more prone to seek intense or immediate stimulation.

Neuroimaging work also provides support for altered reward processing following ACE exposure. Functional MRI studies report reduced activation of the ventral striatum during anticipation or receipt of rewards in individuals with childhood trauma histories.[32] This blunted ventral striatal response has been observed across various types of rewards, including monetary gains and social approval, and in both adolescent and adult samples.[32] Longitudinal studies further suggest that reduced ventral striatal activation during adolescence may help explain associations between early adversity and later depressive symptoms,[32] which themselves are robustly associated with problematic substance use.[33,34] Studies also report altered functional connectivity between reward regions and prefrontal areas, potentially reflecting compensatory or maladaptive attempts at regulation.[32] Although molecular data in humans are more limited, animal models of early stress show enduring changes in dopamine receptor expression and firing patterns in mesolimbic pathways, consistent with a shift in the sensitivity and tuning of the reward system.[32,35]

The clinical implications of a hyporesponsive reward system are substantial. If typical sources of pleasure and motivation fail to produce adequate dopaminergic signaling, individuals may experience chronic anhedonia and low drive,[36] which can make the pharmacological effects of substances especially salient.[35] Psychoactive drugs provide a rapid and large-amplitude increase in dopaminergic activity in the NAc, temporarily overcoming endogenous reward deficits.[35] In this context, substances can function not only as tools for numbing negative affect,[31] but also as means of briefly normalizing a chronically blunted reward state. This dual role, i.e., relief of distress and enhancement of otherwise muted reward, provides a powerful learning signal that can set the stage for repeated use and, eventually, addiction.[8,31]

IMMUNE EMBEDDING OF ACES (PATHWAY 2)

In parallel with these neuroendocrine and neural alterations, early adversity is increasingly understood to leave a durable imprint on the immune system. These alterations can be understood in part through stress-related shifts in autonomic regulation. Repeated activation of the sympathetic branch—which mediates the "fight-or-flight" response—promotes sustained catecholamine release,[37] engaging transcriptional programs that bias immune cells toward proinflammatory gene expression, notably via nuclear factor κB (NF-κB)–mediated signaling.[25] Concurrently, chronic recruitment of the HPA axis can generate persistent elevations in glucocorticoids, fostering partial resistance across time.[25] As this resistance emerges, glucocorticoids lose their typical capacity to restrain inflammatory signaling pathways, including NF-κB, allowing proinflammatory activity to persist.[25] These pressures may help account for the increased basal levels of inflammatory mediators, including interleukin-6 (IL-6), tumor necrosis factor–α (TNF-α), and monocyte chemoattractant protein-1 (MCP-1), commonly observed in ACE-exposed individuals.[25,38-41]

Inflammation, in turn, communicates extensively with the brain. Circulating cytokines can access the central nervous system via humoral routes across the blood–brain barrier,[42] as well as through neural pathways such as vagal afferents.[43] Within the CNS, microglia and other glial cells respond to peripheral inflammatory signals by releasing additional cytokines, reactive oxygen species, and neuroactive metabolites that modulate synaptic plasticity and neurotransmission central to mood and motivation.[44] For example, inflammatory signaling can reduce dopamine synthesis by depleting tetrahydrobiopterin, an essential cofactor for tyrosine hydroxylase, and increase dopamine reuptake through upregulation of presynaptic transporters, effectively dampening dopaminergic tone in striatal regions.[45] In parallel, cytokine-induced activation of the kynurenine pathway can shift tryptophan metabolism toward neuroactive metabolites that influence glutamatergic transmission and neurotoxicity.[46] The net result is a neurochemical milieu characterized by anhedonia, fatigue, and motivational deficits—symptoms that overlap with both depression and early addiction vulnerability.[47]

Importantly, these immune processes may intersect directly with substance exposure. Alcohol, for example, increases intestinal permeability, facilitating translocation of bacterial lipopolysaccharide (LPS) into circulation.[48,49] LPS engages toll-like receptor 4 (TLR4) and stimulates NF-κB–mediated cytokine production, amplifying cytokine release and promoting systemic immune activation.[50] Preclinical models indicate that TLR4 activation enhances alcohol intake, raising the possibility that gut-derived inflammation may feed back to sustain some types of substance use.[51] Human studies similarly show that elevated inflammatory markers such as IL-6 and C-reactive protein are associated with heavier substance use and poorer treatment outcomes. For example, in opioid use disorder, higher circulating IL-6 predicts greater ongoing drug use, poorer methadone adherence, and increased risk of early dropout.[52] Parallel neuroimmune evidence for alcohol use disorder indicates that chronic heavy drinking elevates central cytokines, including MCP-1 and IL-6, and engages neuroinflammatory cascades linked to craving and negative affect.[53] From this perspective, inflammation functions not only as a downstream consequence of ACEs and substance use but may also serve as an active mechanistic contributor that shapes reward sensitivity, negative affect, and craving.

LIMITATIONS OF PRESENT REVIEW

The account developed in this review is necessarily selective. For clarity and space, ACEs were treated as a cumulative exposure, and substance use outcomes were discussed

at an aggregate level, prioritizing shared biological pathways over fine-grained distinctions. Yet both domains are heterogeneous in ways that almost certainly matter for etiology. Different ACE constellations (e.g., threat-related versus deprivation-related exposures) likely engage partially distinct neurodevelopmental mechanisms,[28] even as they converge on overlapping stress, reward, and immune phenotypes. Likewise, alcohol, opioids, stimulants, cannabis, and polysubstance patterns differ in their pharmacology, social context, and temporal course. Collapsing across ACE categories and substances is useful for highlighting general liability but risks obscuring subtype-specific mechanisms and opportunities for tailored intervention. Future work that systematically compares dimensional representations of adversity and profiles of substance use, while simultaneously modeling socioeconomic hardship, community violence, and other socioecological stressors, will be critical for distinguishing what is common versus specific across these pathways.[8,28]

The mechanistic evidence reviewed here also rests on several important methodological constraints. Many of the most detailed biological data are derived from preclinical models that allow precise control of timing, dosage, and context of early stress and drug exposure but cannot fully capture the complexity of human adversity or the social meanings of substance use. Available human studies often rely on retrospective reports of ACEs, which are vulnerable to recall bias and are predominantly observational. Longitudinal cohorts with prospectively assessed adversity, repeated multimodal biomarkers, and careful attention to the timing and chronicity of exposures are relatively rare. Moreover, the present review focused exclusively on biological embedding and did not systematically address developmental processes (e.g., social learning, parental/peer modeling, cultural norms) that interact with biological vulnerabilities to shape real-world use trajectories. Resilience processes were also excluded from the present review. Yet emerging work suggests that supportive caregiving, stable relationships, and resource-rich environments can buffer or even recalibrate regulatory systems following adversity.[54,55] Moving forward, the most informative research will likely be explicitly translational and multilevel: integrating animal and human paradigms; combining neuroendocrine, immune, and neuroimaging measures with dense behavioral and contextual data; using quasi-experimental and causal inference methods where possible; and testing interventions that target stress regulation, reward engagement, and inflammatory processes as modifiable mechanisms. Such work is essential for moving beyond documenting risk to identifying levers that can alter developmental courses set in motion by early adversity.

CONCLUSION

ACEs may increase SUD vulnerability through biological embedding across stress, reward, and immune systems. Although this review focused primarily on ACE-related adaptations, rather than providing a comprehensive synthesis of neurobiology in established SUD, existing addiction research indicates that many of these same systems are perturbed in chronic substance use.[31] For some individuals, then, addiction may emerge in the context of a brain and body already calibrated toward high stress sensitivity, low natural reward, and elevated inflammatory tone, with substance exposure further exaggerating these patterns over time. Viewing SUD through this lens has important implications. Conceptually, it encourages integrated models that bridge developmental trauma research, addiction neuroscience, and psychoneuroimmunology, rather than treating these as siloed literatures. Clinically, it supports trauma-informed, neurobiologically grounded approaches to prevention and treatment.

For ACE-exposed youth at elevated risk, early prevention efforts and interventions that reduce ongoing stress exposure, support caregiving quality, and foster emotion regulation, reward engagement, and health-promoting behaviors may help recalibrate stress, reward, and immune systems before substance use begins. For treatment-seeking adults with significant adversity histories, incorporating strategies that directly target stress dysregulation, reward deficits, and inflammatory burden—alongside traditional substance-focused approaches—may improve outcomes beyond what is achievable with pharmacotherapy or psychosocial treatment alone. Finally, the concept of biological embedding underscores that while early adversity can have profound and lasting effects, these effects are not necessarily irreversible. The same plasticity that allows stress and inflammation to shape developing neural circuits also creates opportunities for repair and adaptation across the life course. Continued research into the mechanisms linking ACEs to SUD, and into interventions capable of modifying those mechanisms, holds promise for reducing the burden of addiction by addressing its developmental roots.

References

1. Felitti VJ, Anda RF, Nordenberg D, Williamson DF, Spitz AM, Edwards V, et al. Relationship of Childhood Abuse and Household Dysfunction to Many of the Leading Causes of Death in Adults. The Adverse Childhood Experiences (ACE) Study. *Am J Prev Med*. 1998 May;14(4):245-58. doi: 10.1016/s0749-3797(98)00017-8. PMID: 9635069.
2. Dube SR, Anda RF, Felitti VJ, Croft JB, Edwards VJ, Giles WH. Growing Up with Parental Alcohol Abuse: Exposure to Childhood Abuse, Neglect, and Household Dysfunction. *Child Abuse Negl*. 2001 Dec;25(12):1627-40. doi: 10.1016/S0145-2134(01)00293-9. PMID: 11814159.
3. Dube SR, Miller JW, Brown DW, Giles WH, Felitti VJ, Dong M, Anda RF. Adverse Childhood Experiences and the Association with Ever Using Alcohol and Initiating Alcohol Use During Adolescence. *J Adolesc Health*. 2006 Apr;38(4):444.e1-e10. doi: 10.1016/j.jadohealth.2005.06.006. PMID: 16549308.

4. Alvanzo AAH, Storr CL, Reboussin B, Green KM, Mojtabai R, La Flair LN, Cullen BA, Susukida R, Seamans M, Crum RM. Adverse Childhood Experiences (ACEs) and Transitions in Stages of Alcohol Involvement Among US Adults: Progression And Regression. *Child Abuse Negl.* 2020 Sep;107:104624. doi: 10.1016/j.chiabu.2020.104624. Epub 2020 Jul 16. PMID: 32683202; PMCID: PMC7968748.
5. Davis JP, Tucker JS, Stein BD, D'Amico EJ. Longitudinal Effects of Adverse Childhood Experiences on Substance Use Transition Patterns During Young Adulthood. *Child Abuse Negl.* 2021 Oct;120:105201. doi: 10.1016/j.chiabu.2021.105201. Epub 2021 Jul 8. PMID: 34245974; PMCID: PMC8384697.
6. Mongan D, Millar SR, Brennan MM, Doyle A, Galvin B, McCarthy N. Longitudinal Associations Between Childhood Adversity and Alcohol Use Behaviours in Early Adulthood: Examining The Mediating Roles of Parental and Peer Relationships. *Child Abuse Negl.* 2025 Mar;161:107302. doi: 10.1016/j.chiabu.2025.107302. Epub 2025 Feb 4. PMID: 39908693.
7. Broekhof R, Nordahl HM, Tanum L, Selvik SG. Adverse Childhood Experiences and Their Association with Substance Use Disorders in Adulthood: A General Population Study (Young-HUNT). *Addict Behav Rep.* 2023 Mar;17:100488. doi: 10.1016/j.abrep.2023.100488. Epub 2023 March 30. PMID: 37077505; PMCID: PMC10106480.
8. Grummitt L, Barrett E, Kelly E, Newton N. An Umbrella Review of the Links Between Adverse Childhood Experiences and Substance Misuse: What, Why, and Where Do We Go from Here? *Subst Abuse Rehabil.* 2022 Nov;13:83-100. doi: 10.2147/sar.S341818. Epub 2022 Nov 15. PMID: 36411791; PMCID: PMC9675346.
9. Bryant DJ, Coman EN, Damian AJ. Association of Adverse Childhood Experiences (ACEs) and Substance Use Disorders (SUDs) in a Multi-Site Safety Net Healthcare Setting. *Addict Behav Rep.* 2020;12:100293. doi: 10.1016/j.abrep.2020.100293.
10. Leza L, Siria S, López-Goñi JJ, Fernández-Montalvo J. Adverse Childhood Experiences (ACEs) and Substance Use Disorder (SUD): A Scoping Review. *Drug Alcohol Depend.* 2021;221:108563. doi: 10.1016/j.drugalcdep.2021.108563. Epub 2021 Jan 29. PMID: 33561668.
11. Borgert B, Morrison DG, Rung JM, Hunt J, Teitelbaum S, Merlo LJ. The Association Between Adverse Childhood Experiences And Treatment Response for Adults with Alcohol and Other Drug Use Disorders. *Am J Addict.* 2023 May;32(3):254-62. doi: 10.1111/ajad.13366. Epub 2022 Dec 25. PMID: 36566359; PMCID: PMC10280781.
12. Fitzpatrick S, Saraiya T, Lopez-Castro T, Ruglass LM, Hien D. The Impact of Trauma Characteristics on Post-Traumatic Stress Disorder and Substance Use Disorder Outcomes Across Integrated and Substance Use Treatments. *J Subst Abuse Treat.* 2020 Jun;113:107976. doi: 10.1016/j.jsat.2020.01.012. Epub 2020 Jan 22. PMID: 32059924; PMCID: PMC7198321.
13. Karsberg S, Hesse M, Pedersen MM, Charak R, Pedersen MU. The Impact of Poly-Traumatization on Treatment Outcomes in Young People with Substance Use Disorders. *BMC Psychiatry.* 2021 Mar 8;21(1):140. doi: 10.1186/s12888-021-03129-x. PMID: 33685430; PMCID: PMC7941934.
14. Shonkoff JP, Boyce WT, McEwen BS. Neuroscience, Molecular Biology, and the Childhood Roots of Health Disparities: Building a New Framework for Health Promotion and Disease Prevention. *JAMA.* 2009 Jun;301(21):2252-9. doi: 10.1001/jama.2009.754. PMID: 19491187.
15. Dube SR, Felitti VJ, Dong M, Chapman DP, Giles WH, Anda RF. Childhood Abuse, Neglect, and Household Dysfunction and the Risk of Illicit Drug Use: The Adverse Childhood Experiences Study. *Pediatrics.* 2003 Mar;111(3):564-72. doi: 10.1542/peds.111.3.564. PMID: 12612237.
16. Felitti VJ, Anda RF, Nordenberg D, Williamson DF, et al. Relationship of Childhood Abuse and Household Dysfunction to Many of the Leading Causes of Death in Adults: The Adverse Childhood Experiences (ACE) Study. *Am J Prev Med.* 1998 May;14(4):245-58. doi: 10.1016/s0749-3797(98)00017-8. PMID: 9635069.
17. Hughes K, Bellis MA, Sethi D, Andrew R, Yon Y, Wood S, Ford K, Baban A, Boderscova L, Kachaeva M, Makaruk K, Markovic M, Povilaitis R, Raleva M, Terzic N, Veleminsky M, Włodarczyk J, Zakhozha V. Adverse Childhood Experiences, Childhood Relationships And Associated Substance Use and Mental Health In Young Europeans. *Eur J Public Health.* 2019 Aug;29(4):741-7. doi: 10.1093/eurpub/ckz037. PMID: 30897194; PMCID: PMC6660110.
18. Jacobson L, Sapolsky R. The Role of the Hippocampus in Feedback Regulation of the Hypothalamic-Pituitary-Adrenocortical Axis. *Endocr Rev.* 1991 May;12(2):118-34. doi: 10.1210/edrv-12-2-118. PMID: 2070776.
19. McEwen BS. Physiology and Neurobiology of Stress and Adaptation: Central Role of the Brain. *Physiol Rev.* 2007 Jul;87(3):873-904. doi: 10.1152/physrev.00041.2006. PMID: 17615391.
20. Fries E, Hesse J, Hellhammer J, Hellhammer DH. A New View on Hypocortisolism. *Psychoneuroendocrinology.* 2005 Nov;30(10):1010-6. doi: 10.1016/j.psyneuen.2005.04.006. PMID: 15950390.
21. Pryce CR, Rüedi-Bettschen D, Dettling AC, Weston A, Russig H, Ferger B, Feldon J. Long-Term Effects of Early-Life Environmental Manipulations in Rodents and Primates: Potential Animal Models in Depression Research. *Neurosci Biobehav Rev.* 2005;29(4-5):649-74. doi: 10.1016/j.neubiorev.2005.03.011. Epub 2005 Apr 25. PMID: 15925698.
22. Heim C, Ehlert U, Hellhammer DH. The Potential Role of Hypocortisolism In the Pathophysiology of Stress-Related Bodily Disorders. *Psychoneuroendocrinology.* 2000 Jan;25(1):1-35. doi: 10.1016/s0306-4530(99)00035-9. PMID: 10633533.
23. Niu L, Gao Q, Xie M, Yip T, Gunnar MR, Wang W, Xu Q, Zhang Y, Lin D. Association of Childhood Adversity with HPA Axis Activity in Children and Adolescents: A Systematic Review and Meta-Analysis. *Neurosci Biobehav Rev.* 2025 May;172:106124. doi: 10.1016/j.neubiorev.2025.106124. Epub 2025 Mar 27. PMID: 40157436.
24. Liu PZ, Nusslock R. How Stress Gets Under the Skin: Early Life Adversity and Glucocorticoid Receptor Epigenetic Regulation. *Curr Genomics.* 2018 Dec;19(8):653-64. doi: 10.2174/1389202919666171228164350. PMID: 30532645; PMCID: PMC6225447.
25. do Prado CH, Grassi-Oliveira R, Daruy-Filho L, Wieck A, Bauer ME. Evidence for Immune Activation and Resistance to Glucocorticoids Following Childhood Maltreatment in Adolescents Without Psychopathology. *Neuropsychopharmacology.* 2017 Oct;42(11):2272-82. doi: 10.1038/npp.2017.137. Epub 2017 Jun 30. PMID: 28664925; PMCID: PMC5603807.
26. McGowan PO, Sasaki A, D'Alessio AC, Dymov S, Labonté B, Szyf M, et al. Epigenetic regulation of the glucocorticoid receptor in human brain associates with childhood abuse. Nat Neurosci. 2009;12:342-348. doi:10.1038/nn.2270.
27. Malave L, van Dijk MT, Anacker C. Early Life Adversity Shapes Neural Circuit Function During Sensitive Postnatal Developmental Periods. *Transl Psychiatry.* 2022 Aug;12(1):306. doi: 10.1038/s41398-022-02092-9. PMID: 35915071; PMCID: PMC9343623.
28. McLaughlin KA, Weissman D, Bitrán D. Childhood Adversity and Neural Development: A Systematic Review. *Annu Rev Dev Psychol.* 2019 Dec;1:277-312. doi: 10.1146/annurev-devpsych-121318-084950. Epub 2019 Dec 12. PMID: 32455344; PMCID: PMC7243625.
29. Hart H, Rubia K. Neuroimaging of Child Abuse: A Critical Review. *Front Hum Neurosci.* 2012 Mar;6:52. doi: 10.3389/fnhum.2012.00052. PMID: 22457645; PMCID: PMC3307045.
30. McLaughlin KA, Sheridan MA, Gold AL, Duys A, Lambert HK, Peverill M, Heleniak C, Shechner T, Wojcieszak Z, Pine DS. Maltreatment Exposure, Brain Structure, and Fear Conditioning in Children and Adolescents. *Neuropsychopharmacology.* 2016 Jul;41(8):1956-64. doi: 10.1038/npp.2015.365. Epub 2015 Dec 18. PMID: 26677946; PMCID: PMC4908632.
31. Juliano VAL, Albernaz-Mariano KA, Covre LHH, Jucá PM, Pereira RM, Shigeo-de-Almeida A, Sampaio LL, Duque EA, Munhoz CD. Neurobiological Intersections of Stress and Substance Use Disorders. *Front Neurosci.* 2025 May;19:1548372. doi: 10.3389/fnins.2025.1548372. PMID: 40376607; PMCID: PMC12078238.
32. Hanson JL, Williams AV, Bangasser DA, Peña CJ. Impact of Early Life Stress on Reward Circuit Function and Regulation. *Front Psychiatry.* 2021 Oct;12:744690. doi: 10.3389/fpsyt.2021.744690. PMID: 34744836; PMCID: PMC8563782.
33. Grant BF, Stinson FS, Dawson DA, Chou SP, Dufour MC, Compton W, Pickering RP, Kaplan K. Prevalence and Co-Occurrence of Substance Use Disorders and Independent Mood and Anxi-

ety Disorders: Results from the National Epidemiologic Survey on Alcohol and Related Conditions. *Arch Gen Psychiatry.* 2004 Aug;61(8):807-16. doi: 10.1001/archpsyc.61.8.807. PMID: 15289279.

34. Kessler RC, Chiu WT, Demler O, Merikangas KR, Walters EE. Prevalence, Severity, and Comorbidity of 12-Month DSM-IV Disorders in the National Comorbidity Survey Replication. *Arch Gen Psychiatry.* 2005 Jun;62(6):617-27. doi: 10.1001/archpsyc.62.6.617. Erratum in: Arch Gen Psychiatry. 2005 Jul;62(7):709. Merikangas, Kathleen R [added]. PMID: 15939839; PMCID: PMC2847357.
35. al'Absi M. The Influence Of Stress and Early Life Adversity on Addiction: Psychobiological Mechanisms of Risk and Resilience. *Int Rev Neurobiol.* 2020;152:71-100. doi: 10.1016/bs.irn.2020.03.012. Epub 2020 May 4. PMID: 32451001; PMCID: PMC9188362.
36. Levis SC, Birnie MT, Bolton JL, Perrone CR, Montesinos JS, Baram TZ, Mahler SV. Enduring Disruption of Reward and Stress Circuit Activities by Early-Life Adversity in Male Rats. *Transl Psychiatry.* 2022 Jun 16;12(1):251. doi: 10.1038/s41398-022-01988-w. PMID: 35705547; PMCID: PMC9200783.
37. Wehrwein EA, Orer HS, Barman SM. Overview of the Anatomy, Physiology, and Pharmacology of the Autonomic Nervous System. *Compr Physiol.* 2016 Jun;6(3):1239-78. doi: 10.1002/cphy.c150037. PMID: 27347892.
38. Kerr DM, McDonald J, Minnis H. The Association of Child Maltreatment and Systemic Inflammation in Adulthood: A Systematic Review. *PLoS One.* 2021 Apr;16(4):e0243685. doi: 10.1371/journal.pone.0243685. PMID: 33831008; PMCID: PMC8031439.
39. Soares S, Rocha V, Kelly-Irving M, Stringhini S, Fraga S. Adverse Childhood Events and Health Biomarkers: A Systematic Review. *Front Public Health.* 2021 Aug;9:649825. doi: 10.3389/fpubh.2021.649825. PMID: 34490175; PMCID: PMC8417002.
40. Li Y, Jinxiang T, Shu Y, Yadong P, Ying L, Meng Y, et al. Childhood trauma and the plasma levels of IL-6, TNF-α are risk factors for major depressive disorder and schizophrenia in adolescents: A cross-sectional and case-control study. J Affect Disord. 2022 May;305:227-232. doi: 10.1016/j.jad.2022.02.020. Epub 2022 Feb 11. PMID: 35151670.
41. de Koning RM, Kuzminskaite E, Vinkers CH, Giltay EJ, Penninx B. Childhood Trauma and LPS-stimulated Inflammation in Adulthood: Results from the Netherlands Study of Depression and Anxiety. *Brain Behav Immun.* 2022 Nov;106:21-29. doi: 10.1016/j.bbi.2022.07.158. Epub 2022 Jul 20. PMID: 35870669.
42. Banks WA. The Blood-Brain Barrier in Neuroimmunology: Tales of Separation and Assimilation. *Brain Behav Immun.* 2015 Feb;44:1-8. doi: 10.1016/j.bbi.2014.08.007. Epub 2014 Aug 27. PMID: 25172555; PMCID: PMC4275374.
43. Pavlov VA, Tracey KJ. The Vagus Nerve and the Inflammatory Reflex--Linking Immunity and Metabolism. *Nat Rev Endocrinol.* 2012 Dec;8(12):743-54. doi: 10.1038/nrendo.2012.189. PMID: 23169440; PMCID: PMC4082307.
44. Block ML, Hong J-S. Microglia and Inflammation-Mediated Neurodegeneration: Multiple Triggers with a Common Mechanism. *Prog Neurobiol.* 2005 Jun;76(2):77-98. doi: 10.1016/j.pneurobio.2005.06.004. PMID: 16081203.
45. Felger JC, Miller AH. Cytokine Effects on the Basal Ganglia and Dopamine Function: The Subcortical Source of Inflammatory Malaise. *Front Neuroendocrinol.* 2012 Aug;33(3):315-27. doi: 10.1016/j.yfrne.2012.09.003. Epub 2012 Sep 21. PMID: 23000204; PMCID: PMC3484236.
46. Dantzer R, O'Connor JC, Freund GG, Johnson RW, Kelley KW. From Inflammation to Sickness and Depression: When The Immune System Subjugates The Brain. *Nat Rev Neurosci.* 2008 Jan;9(1):46-56. doi: 10.1038/nrn2297. PMID: 18073775; PMCID: PMC2919277.
47. Kelley KW, Dantzer R. Alcoholism and Inflammation: Neuroimmunology of Behavioral and Mood Disorders. *Brain Behav Immun.* 2011 Jun;25 Suppl 1:S13-20. doi: 10.1016/j.bbi.2010.12.013. Epub 2010 Dec 28. PMID: 21193024; PMCID: PMC4068736.
48. Brenchley JM, Douek DC. Microbial Translocation Across the GI Tract. *Annu Rev Immunol.* 2012;30:149-73. doi: 10.1146/annurev-immunol-020711-075001. Epub 2012 Jan 3. PMID: 22224779; PMCID: PMC3513328.
49. Szabo G, Bala S. Alcoholic Liver Disease and the Gut-Liver Axis. *World J Gastroenterol.* 2010 Mar;16(11):1321-9. doi: 10.3748/wjg.v16.i11.1321. PMID: 20238398; PMCID: PMC2842523.
50. Park BS, Lee JO. Recognition of Lipopolysaccharide Pattern by TLR4 Complexes. *Exp Mol Med.* 2013 Dec 6;45(12):e66. doi: 10.1038/emm.2013.97. PMID: 24310172; PMCID: PMC3880462.
51. Blednov YA, Benavidez JM, Geil C, Perra S, Morikawa H, Harris RA. Activation of Inflammatory Signaling by Lipopolysaccharide Produces a Prolonged Increase of Voluntary Alcohol Intake in Mice. *Brain Behav Immun.* 2011 Jun;25 Suppl 1(Suppl 1):S92-S105. doi: 10.1016/j.bbi.2011.01.008. Epub 2011 Jan 23. PMID: 21266194; PMCID: PMC3098320.
52. Lu RB, Wang TY, Lee SY, Chen SL, Chang YH, See Chen P, Lin SH, Chu CH, Huang SY, Tzeng NS, Lee IH, Chin Chen K, Kuang Yang Y, Chen P, Chen SH, Hong JS. Correlation Between Interleukin-6 Levels and Methadone Maintenance Therapy Outcomes. *Drug Alcohol Depend.* 2019 Nov 1;204:107516. doi: 10.1016/j.drugalcdep.2019.06.018. Epub 2019 Aug 30. PMID: 31513981; PMCID: PMC7077753.
53. Lékó AH, Ray LA, Leggio L. The Vicious Cycle Between (Neuro) Inflammation and Alcohol Use Disorder: An Opportunity to Develop New Medications? *Alcohol Clin Exp Res (Hoboken).* 2023 May;47(5):843-847. doi: 10.1111/acer.15049. Epub 2023 Mar 15. PMID: 36882163; PMCID: PMC10289133.
54. Hostinar CE, Sullivan RM, Gunnar MR. Psychobiological Mechanisms Underlying the Social Buffering of the Hypothalamic-Pituitary-Adrenocortical Axis: A Review of Animal Models and Human Studies Across Development. *Psychol Bull.* 2014 Jan;140(1):256-82. doi: 10.1037/a0032671. Epub 2013 Apr 22. PMID: 23607429; PMCID: PMC3844011.
55. Colich NL, Sheridan MA, Humphreys KL, Wade M, Tibu F, Nelson CA, Zeanah CH, Fox NA, McLaughlin KA. Heightened Sensitivity to the Caregiving Environment During Adolescence: Implications for Recovery Following Early-Life Adversity. *J Child Psychol Psychiatry.* 2021 Aug;62(8). doi: 10.1111/jcpp.13347. Epub 2020 Nov 20. PMID: 33215715; PMCID: PMC8134501.

Authors

Samantha E. Clark, MA, Center for Alcohol and Addiction Studies, Brown University, Providence, RI.

Mollie A. Monnig, PhD, Center for Alcohol and Addiction Studies, Brown University, Providence, RI.

Peter M. Monti, PhD, Center for Alcohol and Addiction Studies, Brown University, Providence, RI.

Disclosures

Competing Interests: The authors declare they have no competing interests to disclose.

Funding Acknowledgment: Preparation of this report was supported by an Institutional Development Award from the National Institute of General Medical Sciences of the National Institutes of Health under grant P20GM130414 (PI: Monti) and the National Institute on Alcohol Abuse and Alcoholism grant R01AA031640 (PI: Monnig).

Disclaimer: The content is solely the responsibility of the authors and does not necessarily represent official views of the National Institutes of Health.

Ethical Approvals: Ethical approval, as would be obtained from an Institutional Review Board, was not applicable for this article.

Correspondence

Samantha E. Clark, MA
Box G-S121-3
Brown University
Providence, RI 02912
samantha_clark1@brown.edu